ASCO, ASTRO, Release New Guidelines for Treatment of Type of Bladder Cancer


New guidelines have been created involving urology and radiation strategies for the treatment of non-metastatic muscle-invasive bladder cancer, to be presented at the 2017 American Urological Association (AUA) Annual Meeting (May 12-16, 2017; Boston, MA).


Related Content

ASCO endorses EAU guidelines for muscle-invasive, metastatic bladder cancer

New bladder cancer guidelines from AUA, SUO released


The guideline is the result of a joint committee comprised by members of the AUA, the American Society of Clinical Oncology (ASCO), the American Society of Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO). It is the first time these 4 groups have convened to develop a joint cancer guideline that provides instruction to clinicians on diagnosis, treatment, and patient surveillance of non-metastatic muscle-invasive bladder cancer.

"Thousands of patients are diagnosed with bladder cancer each year and 25% of those patients have muscle-invasive disease that traditionally has a low survival rate," said Sam S Chang, MD, MBA, chair of the guideline panel, in a press release (April 13, 2017). "We know that, in order to achieve the best outcomes, we must take a multi-disciplinary, collaborative approach. This joint guideline brings together urology and urologic surgeons, medical oncology, as well as radiation oncology to help guide that approach."

The guideline makes recommendations regarding initial patient evaluation and counseling, including optimal utilization of laboratory and imaging diagnostics as well as staging tests and procedures such as genitourinary pathology and physical exams. Additionally, the guideline covers treatment practices (surgery, chemotherapy, and radiation) and patient surveillance and follow-up, including post-treatment surveillance techniques, quality of life concerns, and supportive care counseling.

Furthermore, approaches to bladder preservation and special considerations for patients diagnosed with variant histology are addressed in the guideline.

"By bringing our specialties together, we've integrated evidence-based statements, expert opinions and patient desires and interests into what we believe to be a strong clinical framework for the management of non-metastatic muscle-invasive bladder cancer," said Jeff Holzbeierlein, MD, FACS, vice chair of the guideline panel.

The full guideline is available on the AUA website. – Zachary Bessette